TTP develops dose counter for AstraZeneca’s Symbicort® inhaler

Identifying risks early in the product development process is crucial for ensuring smooth, surprise-free project outcomes when scaling drug delivery devices. Iain McDerment outlines the first-principles approach to the R&D process, applying rigorous modelling and experimentation to reduce risks – rapidly developing a highly reliable, safety-critical dose counter.